BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+6.01%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.04B
AUM Growth
+$9.04B
(-3.5%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-1.97%
Top 10 Holdings %
Top 10 Hldgs %
81.82%
Holding
99
New
4
Increased
11
Reduced
16
Closed
9
Top Buys
| 1 |
Immunovant
IMVT
|
$64.1M |
| 2 |
Insmed
INSM
|
$28.5M |
| 3 |
Immunocore
IMCR
|
$24M |
| 4 |
Vaxcyte
PCVX
|
$22.4M |
| 5 |
Celcuity
CELC
|
$16M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$199M |
| 2 |
Krystal Biotech
KRYS
|
$26.6M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$25.4M |
| 4 |
CRISPR Therapeutics
CRSP
|
$22.3M |
| 5 |
Akero Therapeutics
AKRO
|
$22.2M |
Sector Composition
| 1 | Healthcare | 98.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONC
1
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.39B | 26.5% | 8,799,053 -732,827 | -8% | -$199M |
|
2
Incyte
INCY
$16.5B
| $1.86B | 20.6% | 30,739,953 +487 | +0% | +$29.5K |
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $712M | 7.88% | 42,877,916 | – | – |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $654M | 7.24% | 1,974,590 | – | – |
|
5
Summit Therapeutics
SMMT
$17.6B
| $471M | 5.21% | 24,424,865 | – | – |
|
|
6
Insmed
INSM
$28.8B
| $410M | 4.54% | 5,380,626 +373,763 | +7% | +$28.5M |
|
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $297M | 3.29% | 5,604,483 -479,766 | -8% | -$25.4M |
|
8
Revolution Medicines
RVMD
$7.1B
| $281M | 3.11% | 7,936,972 | – | – |
|
9
Kymera Therapeutics
KYMR
$2.95B
| $164M | 1.82% | 5,995,929 | – | – |
|
10
Alkermes
ALKS
$4.78B
| $148M | 1.64% | 4,483,285 +301,534 | +7% | +$9.96M |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $135M | 1.5% | 6,155,940 | – | – |
|
12
Replimune Group
REPL
$422M
| $108M | 1.19% | 11,045,336 | – | – |
|
|
13
Immunovant
IMVT
$2.56B
| $93.3M | 1.03% | 5,457,881 +3,750,000 | +220% | +$64.1M |
|
|
BCYC
14
Bicycle Therapeutics
BCYC
$511M
| $92.4M | 1.02% | 10,885,357 | – | – |
|
|
15
Immunocore
IMCR
$1.62B
| $68.9M | 0.76% | 2,322,656 +807,338 | +53% | +$24M |
|
16
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $62.6M | 0.69% | 2,818,323 | – | – |
|
17
AbCellera Biologics
ABCL
$1.25B
| $61.4M | 0.68% | 27,525,640 | – | – |
|
18
Ultragenyx Pharmaceutical
RARE
$2.89B
| $57.1M | 0.63% | 1,576,114 | – | – |
|
19
Denali Therapeutics
DNLI
$2.23B
| $50.7M | 0.56% | 3,731,695 | – | – |
|
20
Kodiak Sciences
KOD
$478M
| $48.6M | 0.54% | 17,310,490 | – | – |
|
21
Nurix Therapeutics
NRIX
$714M
| $46.1M | 0.51% | 3,882,125 | – | – |
|
22
argenx
ARGX
$43.6B
| $46M | 0.51% | 77,760 -34,144 | -31% | -$20.2M |
|
23
Entrada Therapeutics
TRDA
$208M
| $44M | 0.49% | 4,865,819 | – | – |
|
|
24
Celcuity
CELC
$2.17B
| $43M | 0.48% | 4,257,735 +1,579,182 | +59% | +$16M |
|
|
GRAL
25
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $41.6M | 0.46% | 1,630,125 | – | – |
|